A breakthrough in trade talks with the U.S. might win Ishiba a reprieve, but so far there's been scant sign of progress in negotiating away the threat of higher tariffs on Japan's exports to the U.S.

George Tidmarsh appointed to lead FDA drug review division amid staffing cuts and scrutiny over accelerated approvals and ...

US stocks remain narrowly mixed amid more earnings reports. Investors are looking for impact of Trump's tariffs. Chip stocks weigh on Nasdaq, S&P 500.